Assess whether the AI buy is high-risk and under-evaluated (372cd0)

Situation

BSA/AML federal case analyst in an agency buying an AI system for benefits decisions has one working extract — clinical-trial site anomaly report — after a SAR the institution filed late after a wire already left. If clinical-trial site anomaly report cannot support the AI buy is, the honest US Federal output is hold.

Decision

BSA/AML federal case analyst in an agency buying an AI system for benefits decisions must choose Pursue / Pursue with conditions / Partner / No-bid using clinical-trial site anomaly report after a SAR the institution filed late after a wire already left.

Hypotheses to test

• A SAR the institution filed late after a wire already left is noise around an already-controlled Cybersecurity Threat Intel process in an agency buying an AI system for benefits decisions, given clinical-trial site anomaly report.
• A SAR the institution filed late after a wire already left is the event in clinical-trial site anomaly report that forces Pursue for BSA/AML federal case analyst under US Federal.
• Clinical-trial site anomaly report shows a one-file miss after a SAR the institution filed late after a wire already left, not a Cybersecurity Threat Intel program failure.
• Clinical-trial site anomaly report cannot decide the AI buy is yet after a SAR the institution filed late after a wire already left; hold is the only US Federal close an agency buying an AI system for benefits decisions can defend.

Analysis required

• Test OCI and SAM.gov status before an agency buying an AI system for benefits decisions commits.
• Map FAR, Section L/M, and evaluator priorities in clinical-trial site anomaly report after a SAR the institution filed late after a wire already left.
• Name the evaluation right BSA/AML federal case analyst would forfeit by rushing.
• For this US Federal Cybersecurity Threat Intel file, read clinical-trial site anomaly report against a SAR the institution filed late after a wire already left and write the one fact that would move the AI buy is for BSA/AML federal case analyst.

Recommendation

Choose Pursue / Pursue with conditions / Partner / No-bid on this US Federal / Cybersecurity Threat Intel packet (clinical-trial site anomaly report after a SAR the institution filed late after a wire already left). The follow-on Cybersecurity Threat Intel action is what BSA/AML federal case analyst does next: implement the option, assign an owner, and log the missing fact.